A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

← catalyst calendar

NCT05206773

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

122actual

Sites

Countries

Argentina, Australia, Austria +18

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-03-11

actual

When the study began enrolling

Primary completion

2025-12-17

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-01-04

estimated

The whole study's end, after follow-up

First posted

2022-01-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Fabry Disease

Interventions

Drug: Venglustat (GZ402671)
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Percent change from baseline at 6 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)

measured From baseline to 6 months

Percent change from baseline at 12 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)

measured From baseline to 12 months

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed